Erratum: Expression of concern: P63 promotes cell survival through fatty acid synthase (PLoS ONE (2019)4:6(e5877) Doi: 10.1371/journal.pone.0005877);p63 promotes cell survival through fatty acid synthase

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Sabbisetti, Venkata ^a,b   Di Napoli, Arianna ^a   Seeley, Apryle ^a,b   Amato, Angela M ^a   O'Regan, Esther ^c   Ghebremichael, Musie ^b   Loda, Massimo ^a,b   Signoretti, Sabina ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE; PROTEIN KINASE B; PROTEIN P63; CKAP4 PROTEIN, HUMAN; DNA BINDING PROTEIN; ISOPROTEIN; MEMBRANE PROTEIN; MYRISTIC ACID DERIVATIVE; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE SILENCING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ORGANOGENESIS; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; BIOLOGICAL MODEL; CELL CYCLE; EPITHELIUM CELL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; EPITHELIAL CELLS; FATTY ACID SYNTHETASE COMPLEX; GENE SILENCING; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; MYRISTIC ACIDS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEINS;

EID: 67650077386     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0219869     Document Type: Erratum

References (65)

1. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316.
2. Schmale H, Bamberger C (1997) A novel protein with strong homology to the tumor suppressor p53. Oncogene 15: 1363-1367.
3. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, et al. (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 4: 839-843.
4. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.
5. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, et al. (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157: 1769-1775.
6. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, et al. (2000) Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 60: 4016-4020.
7. DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, et al. (2002) Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 62: 89-98.
8. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, et al. (2002) p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8: 494-501.
9. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, et al. (2005) p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A 102: 11355-11360.
10. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713.
11. Senoo M, Pinto F, Crum CP, McKeon F (2007) p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129: 523-536.
12. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, et al. (2002) Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161: 1199-1206.
13. Mills AA (2006) p63: oncogene or tumor suppressor? Curr Opin Genet Dev 16: 38-44.
14. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, et al. (2006) p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci U S A 103: 8435-8440.
15. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, et al. (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 97: 5462-5467.
16. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, et al. (2005) Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363-373.
17. Yamaguchi K, Wu L, Caballero OL, Hibi K, Trink B, et al. (2000) Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int J Cancer 86: 684-689.
18. Parsa R, Yang A, McKeon F, Green H (1999) Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 113: 1099-1105.
19. Park BJ, Lee SJ, Kim JI, Lee SJ, Lee CH, et al. (2000) Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 60: 3370-3374.
20. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, et al. (2002) Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 33: 158-164.
21. Chan WM, Siu WY, Lau A, Poon RY (2004) How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 24: 3536-3551.
22. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW (2006) p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9: 45-56.
23. Yan W, Chen X (2006) GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. J Biol Chem 281: 7856-7862.
24. Wu G, Osada M, Guo Z, Fomenkov A, Begum S, et al. (2005) DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res 65: 758-766.
25. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA (2003) The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 23: 2264-2276.
26. Ortt K, Raveh E, Gat U, Sinha S (2008) A chromatin immunoprecipitation screen in mouse keratinocytes reveals Runx1 as a direct transcriptional target of DeltaNp63. J Cell Biochem 104: 1204-1219.
27. Lopardo T, Lo Iacono N, Marinari B, Giustizieri ML, Cyr DG, et al. (2008) Claudin-1 is a p63 target gene with a crucial role in epithelial development. PLoS ONE 3: e2715.
28. Candi E, Rufini A, Terrinoni A, Giamboi-Miraglia A, Lena AM, et al. (2007) DeltaNp63 regulates thymic development through enhanced expression of FgfR2 and Jag2. Proc Natl Acad Sci U S A 104: 11999-12004.
29. Barbieri CE, Perez CA, Johnson KN, Ely KA, Billheimer D, et al. (2005) IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res 65: 2314-2320.
30. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, et al. (2006) p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 8: 551-561.
31. Wakil SJ (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28: 4523-4530.
32. D'Erchia AM, Tullo A, Lefkimmiatis K, Saccone C, Sbisa E (2006) The fatty acid synthase gene is a conserved p53 family target from worm to human. Cell Cycle 5: 750-758.
33. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, et al. (2004) Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64: 8867-8875.
34. Bolker HI, Fishman S, Heard RD, O'Donnell VJ, Webb JL, et al. (1956) The incorporation of acetate-1-C14 into cholesterol and fatty acids by surviving tissues of normal and scorbutic guinea pigs. J Exp Med 103: 199-205.
35. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
36. Scarpino S, Di Napoli A, Melotti F, Talerico C, Cancrini A, et al. (2007) Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol 212: 411-419.
37. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, et al. (2005) Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24: 3574-3582.
38. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279: 80-90.
39. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV (2002) Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62: 642-646.
40. Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, et al. (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24: 6465-6481.
41. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18: 126-131.
42. Chirala SS, Chang H, Matzuk M, Abu-Elheiga L, Mao J, et al. (2003) Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci U S A 100: 6358-6363.
43. Visca P, Sebastiani V, Botti C, Diodoro MG, Lasagni RP, et al. (2004) Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res 24: 4169-4173.
44. Takahiro T, Shinichi K, Toshimitsu S (2003) Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 9: 2204-2212.
45. Shah US, Dhir R, Gollin SM, Chandran UR, Lewis D, et al. (2006) Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol 37: 401-409.
46. Rossi S, Ou W, Tang D, Bhattacharya N, Dei Tos AP, et al. (2006) Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol 209: 369-375.
47. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, et al. (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1: 707-715.
48. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777.
49. Gansler TS, Hardman W 3rd, Hunt DA, Schaffel S, Hennigar RA (1997) Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28: 686-692.
50. Agostini M, Silva SD, Zecchin KG, Coletta RD, Jorge J, et al. (2004) Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells. Oral Oncol 40: 728-735.
51. Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF (1998) Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 58: 4611-4615.
52. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, et al. (2001) Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 61: 1493-1499.
53. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, et al. (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 97: 3450-3454.
54. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64: 2070-2075.
55. Furuya Y, Akimoto S, Yasuda K, Ito H (1997) Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis. Anticancer Res 17: 4589-4593.
56. Carvalho MA, Zecchin KG, Seguin F, Bastos DC, Agostini M, et al. (2008) Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer 123: 2557-2565.
57. Migita T, Ruiz S, Fornari A, Inazuka F, Fiorentino M, et al. (In press) Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. J Natl Cancer Inst.
58. Ogawa E, Okuyama R, Ikawa S, Nagoshi H, Egawa T, et al. (2008) p51/p63 Inhibits ultraviolet B-induced apoptosis via Akt activation. Oncogene 27: 848-856.
59. Van de Sande T, Roskams T, Lerut E, Joniau S, Van Poppel H, et al. (2005) High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/ PKB. J Pathol 206: 214-219.
60. Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R (2004) Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/ neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog 41: 164-178.
61. Bandyopadhyay S, Pai SK, Watabe M, Gross SC, Hirota S, et al. (2005) FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 24: 5389-5395.
62. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, et al. (2004) Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol 24: 1369-1383.
63. Swinnen JV, Heemers H, Deboel L, Foufelle F, Heyns W, et al. (2000) Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19: 5173-5181.
64. Oskouian B (2000) Overexpression of fatty acid synthase in SKBR3 breast cancer cell line is mediated via a transcriptional mechanism. Cancer Lett 149: 43-51.
65. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM (2003) Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63: 132-139.